Extendicare (TSE:EXE - Get Free Report) had its target price hoisted by investment analysts at National Bankshares from C$16.10 to C$17.50 in a report issued on Wednesday,BayStreet.CA reports. The brokerage currently has an "outperform" rating on the stock. National Bankshares' target price points to a potential upside of 17.77% from the company's current price.
EXE has been the topic of several other research reports. Cibc World Mkts raised shares of Extendicare to a "strong-buy" rating in a research note on Monday, September 22nd. CIBC set a C$18.00 price objective on shares of Extendicare and gave the stock an "outperform" rating in a research note on Monday, September 22nd. Finally, National Bank Financial raised shares of Extendicare to a "strong-buy" rating in a research note on Wednesday, July 16th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of C$15.20.
View Our Latest Stock Report on EXE
Extendicare Trading Up 0.1%
Shares of TSE EXE traded up C$0.02 during midday trading on Wednesday, hitting C$14.86. 122,845 shares of the company traded hands, compared to its average volume of 183,081. Extendicare has a 12-month low of C$8.96 and a 12-month high of C$15.32. The company has a debt-to-equity ratio of 283.02, a quick ratio of 0.98 and a current ratio of 0.62. The stock has a 50-day moving average price of C$13.48 and a 200 day moving average price of C$13.59. The firm has a market cap of C$1.25 billion, a P/E ratio of 15.40 and a beta of 0.88.
About Extendicare
(
Get Free Report)
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Extendicare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.
While Extendicare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.